促卵泡生成素受体（FSHR）Ser680Asn基因型不影响使用不同促性腺激素制剂诱导排卵的刺激周期中卵泡液激素谱：一项初步研究。
Follicle-Stimulating Hormone Receptor (FSHR) Ser680Asn Genotype Does Not Affect the Follicular Fluid Hormonal Profile in Stimulated Cycles Using Different Gonadotropin Preparations for Ovulation Induction: A Pilot Study.
作者信息
Papamentzelopoulou Myrto-Sotiria, Mavrogianni Despoina, Liokari Emmanouela, Stavros Sofoklis, Potiris Anastasios, Doumplis Dimitris, Loutradis Dimitrios
机构信息
1st Department of Obstetrics and Gynecology, Alexandra General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, GRC.
Department of Obstetrics and Gynecology, Fertility Institute, Athens, GRC.
出版信息
Cureus. 2024 Jun 10;16(6):e62116. doi: 10.7759/cureus.62116. eCollection 2024 Jun.
BACKGROUND
The existing literature lacks consensus on the effectiveness of utilizing polymorphisms to enhance outcomes in in vitro fertilization (IVF), particularly regarding ovulation induction protocols, oocyte and embryo quality, and pregnancy rates. Therefore, the present pilot study aims to assess whether the composition of different gonadotropin preparations affects the ovarian stimulation protocol concerning follicle-stimulating hormone receptor () Ser680Asn genotypes (Ser/Ser, Ser/Asn, and Asn/Asn), in terms of ovulation induction parameters, including oocyte maturation rate, embryo quality, and pregnancy rate.
METHODOLOGY
A total of 94 IVF patients underwent treatment using a GnRH antagonist protocol with four distinct gonadotropin preparations: HMG, HMG/hCG, rFSH, and rFSH/hCG. Follicular fluid (FF) samples were pooled for each patient for analysis.
RESULTS
No statistical differences in the FF hormonal profile (progesterone, testosterone, androstenedione, estradiol, FSH, hCG) among the genotypes were reported either separately for each protocol or in combination for the four different preparations of gonadotropins. The maturation rate of MII oocytes and embryo quality did not differ among women carrying either Ser/Ser, Ser/Asn, or Asn/Asn genotype (p-value=0.475, and p-value=1.000, respectively). Moreover, no statistically significant correlation was revealed among Ser/Ser, Ser/Asn, and Asn/Asn carriers and pregnancy rate (p = 0.588).
CONCLUSIONS
FF hormonal analysis of women undergoing IVF using different ovulation induction protocols and carrying either Ser/Ser, Ser/Asn, or Asn/Asn genotype revealed no significant correlations, in terms of maturation rate of MII oocytes, embryo quality, and pregnancy rate, indicating that the Ser680Asn genotype does not constitute a biomarker for a positive pregnancy outcome. Therefore, the existence of a different mechanism for the expression of Ser680Asn genotypes in the FF hormonal profile related to stimulated cycles is implied.
背景
现有文献对于利用基因多态性来改善体外受精（IVF）结局的有效性尚未达成共识，尤其是在促排卵方案、卵母细胞和胚胎质量以及妊娠率方面。因此，本前瞻性研究旨在评估不同促性腺激素制剂的成分是否会影响与促卵泡激素受体（FSHR）Ser680Asn基因型（Ser/Ser、Ser/Asn和Asn/Asn）相关的卵巢刺激方案，具体涉及排卵诱导参数，包括卵母细胞成熟率、胚胎质量和妊娠率。
方法
共有94例IVF患者采用GnRH拮抗剂方案，使用四种不同的促性腺激素制剂进行治疗：HMG、HMG/hCG、rFSH和rFSH/hCG。收集每位患者的卵泡液（FF）样本进行分析。
结果
无论是单独针对每种方案还是将四种不同的促性腺激素制剂组合起来，在各基因型之间，卵泡液激素谱（孕酮、睾酮、雄烯二酮、雌二醇、FSH、hCG）均未报告有统计学差异。携带Ser/Ser、Ser/Asn或Asn/Asn基因型的女性中，MII期卵母细胞的成熟率和胚胎质量没有差异（p值分别为0.475和1.000）。此外，Ser/Ser、Ser/Asn和Asn/Asn携带者与妊娠率之间未显示出统计学上的显著相关性（p = 0.588）。
结论
对采用不同排卵诱导方案且携带Ser/Ser、Ser/Asn或Asn/Asn基因型的IVF女性进行卵泡液激素分析发现，在MII期卵母细胞成熟率、胚胎质量和妊娠率方面均无显著相关性，这表明FSHR Ser680Asn基因型并非妊娠阳性结局的生物标志物。因此，这意味着在与刺激周期相关的卵泡液激素谱中，FSHR Ser680Asn基因型的表达存在不同机制。
Zotero 插件